Sun Pharmaceutical Industries Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹4.51 lakh crore. The company reports ROE of 13.1%, a net profit margin of 17.8%. Revenue grew +11.9% year-over-year. Promoter holding stands at 55.6%, with FII participation at 29.5%.
Price is rising consistently (EMA alignment — short and medium-term averages both pointing up). Buying pressure is building (RSI/MACD momentum confirmed). A trend-following indicator is on the bullish side (SuperTrend signal: buy). The uptrend is visible even on the weekly chart (longer-term trend confirmed). Above-average delivery percentage suggests real buying, not just speculation (delivery 63%). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Foreign institutions have been net buyers for 3 consecutive days — sustained institutional demand (✅ FII buying streak).
Sun Pharmaceutical Industries Limited scores 84/100 (High Conviction Research Signal). The strongest signals are Trend (17/100) and Momentum (13/100). The weakest dimension is Valuation (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.
| Stock | Score | Signal |
|---|---|---|
|
AUROPHARMA
Aurobindo Pharma Limited
|
75 | High Conviction |
|
APOLLOHOSP
Apollo Hospitals Enterprise Limited
|
73 | High Conviction |
|
DIVISLAB
Divi's Laboratories Limited
|
72 | High Conviction |
|
CIPLA
Cipla Limited
|
69 | Positive Setup |
|
GLENMARK
Glenmark Pharmaceuticals Limited
|
60 | Positive Setup |